|Articles|October 28, 2020
In vitro glycoengineering – Suitability for BioPharma manufacturing
Author(s)Roche
Glycosylation homogeneity and pattern can be increase with cell line engineering and bioprocess optimization. But, these can be time-consuming and might compromise yield. In vitro glycoengineering can solve these problems and is independent from the cell line and the bioprocess used.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
EU Clears Subcutaneous Biologic for Lupus, Advancing Patient-Controlled Delivery
2
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
3
Two-Minute Mysteries: BioPharm Stories - Episode 2: The Costly Myth of Noninvasive Glucose Monitoring
4
Developing Next-Gen Cell Lines Using Targeted Integration
5